Protection against SARS-CoV-2 Beta variant in mRNA-1273 vaccine–boosted nonhuman primates-Reference-Cited by-同舟云学术

Protection against SARS-CoV-2 Beta variant in mRNA-1273 vaccine–boosted nonhuman primates

Published:2021-12-10 Issue:6573 Volume:374 Page:1343-1353
ISSN:0036-8075
Container-title:Science
language:en
Short-container-title:Science

Author:

Corbett Kizzmekia S.¹^ORCID,Gagne Matthew¹^ORCID,Wagner Danielle A.¹^ORCID,O’ Connell Sarah¹,Narpala Sandeep R.¹^ORCID,Flebbe Dillon R.¹,Andrew Shayne F.¹^ORCID,Davis Rachel L.¹,Flynn Barbara¹,Johnston Timothy S.¹^ORCID,Stringham Christopher D.¹^ORCID,Lai Lilin²,Valentin Daniel³,Van Ry Alex³^ORCID,Flinchbaugh Zackery³,Werner Anne P.¹,Moliva Juan I.¹,Sriparna Manjari¹^ORCID,O’Dell Sijy¹,Schmidt Stephen D.¹^ORCID,Tucker Courtney¹,Choi Angela⁴^ORCID,Koch Matthew⁴,Bock Kevin W.⁵^ORCID,Minai Mahnaz⁵^ORCID,Nagata Bianca M.⁵^ORCID,Alvarado Gabriela S.¹,Henry Amy R.¹,Laboune Farida¹,Schramm Chaim A.¹,Zhang Yi¹^ORCID,Yang Eun Sung¹^ORCID,Wang Lingshu¹^ORCID,Choe Misook¹^ORCID,Boyoglu-Barnum Seyhan¹,Wei Shi¹^ORCID,Lamb Evan¹^ORCID,Nurmukhambetova Saule T.¹,Provost Samantha J.¹,Donaldson Mitzi M.¹,Marquez Josue¹,Todd John-Paul M.¹^ORCID,Cook Anthony³,Dodson Alan³^ORCID,Pekosz Andrew⁶^ORCID,Boritz Eli¹^ORCID,Ploquin Aurélie¹,Doria-Rose Nicole¹^ORCID,Pessaint Laurent³^ORCID,Andersen Hanne³^ORCID,Foulds Kathryn E.¹^ORCID,Misasi John¹^ORCID,Wu Kai⁴,Carfi Andrea⁴,Nason Martha C.⁷^ORCID,Mascola John¹^ORCID,Moore Ian N.⁵^ORCID,Edwards Darin K.⁴,Lewis Mark G.³^ORCID,Suthar Mehul S.²^ORCID,Roederer Mario¹^ORCID,McDermott Adrian¹^ORCID,Douek Daniel C.¹,Sullivan Nancy J.¹^ORCID,Graham Barney S.¹^ORCID,Seder Robert A.¹^ORCID

Affiliation:

1. Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.

2. Center for Childhood Infections and Vaccines of Children’s Healthcare of Atlanta, Department of Pediatrics, Department of Microbiology and Immunology, Emory Vaccine Center, Emory University, Atlanta, GA 30322, USA.

3. BIOQUAL Inc., Rockville, MD 20850, USA.

4. Moderna Inc., Cambridge, MA 02139, USA.

5. Infectious Disease Pathogenesis Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.

6. Department of Microbiology and Immunology, Johns Hopkins University, Bloomberg School of Public Health, Baltimore, MD 21205, USA.

7. Biostatistics Research Branch, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.

Abstract

A look at variant-specific boosters The evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs) has raised the question of whether current COVID-19 vaccines protect against VOCs and if a variant specific vaccine may be needed. Of the currently identified VOCs, the Delta variant is believed to be the most transmissible, whereas the Beta variant appears to be the most vaccine resistant. Corbett et al . looked at the effect of vaccine boosting using either the original WA-1 strain vaccine or a Beta variant–specific booster. Around 6 months after the primary two-dose vaccine series, a third boost vaccination resulted in higher neutralizing antibody levels against VOCs in nonhuman primates. Regardless of whether the boost was from the original vaccine or the Beta-specific version, similar increases in neutralizing antibody levels were observed and resulted in enhanced viral protection. —PNK

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference46 articles.

1. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

2. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

3. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

4. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

5. Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine

Cited by 76 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Three immunizations with Novavax’s protein vaccines increase antibody breadth and provide durable protection from SARS-CoV-2;npj Vaccines;2024-01-20

2. Diverse array of neutralizing antibodies elicited upon Spike Ferritin Nanoparticle vaccination in rhesus macaques;Nature Communications;2024-01-03

3. Interaction dynamics between innate and adaptive immune cells responding to SARS-CoV-2 vaccination in non-human primates;Nature Communications;2023-12-02

4. Durable immunity to SARS-CoV-2 in both lower and upper airways achieved with a gorilla adenovirus (GRAd) S-2P vaccine in non-human primates;2023-11-22

5. Mucosal Adenoviral-vectored Vaccine Boosting Durably Prevents XBB.1.16 Infection in Nonhuman Primates;2023-11-08